Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?

2012 ◽  
Vol 19 (10) ◽  
pp. 677-684 ◽  
Author(s):  
J. A. Holmes ◽  
P. V. Desmond ◽  
A. J. Thompson
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Hepatitis C Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting

Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy

2019 ◽  
Vol 53 (5) ◽  
pp. 559-563 ◽  
Author(s):  
Simone Lanini ◽  
Paola Scognamiglio ◽  
Raffaella Pisapia ◽  
Claudia Minosse ◽  
Alessandro Agresta ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Hepatitis C Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals Direct-acting Antiviral Therapy for Mixed Genotype Chronic Hepatitis C Infection

2019 ◽  
Vol 25 (2) ◽  
pp. 55-58
Author(s):  
Bedia Mutay Suntur ◽  
Nevzat Ünal ◽  
Hava Kaya ◽  
Banu Kara ◽  
Halime Betül Şahin Eker
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Hepatitis C Infection ◽  
Mixed Genotype ◽  
Direct Acting Antiviral ◽  
Direct Acting

Changes in Serum Level of Autotaxin with Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Khaled Mohamed Hussein Abdelwahab ◽  
Shereen Abou Bakr Saleh ◽  
Ghada Abdelrahman Ahmed ◽  
Asmaa Mady Gomaa Mady
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Serum Level ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Antiviral Treatment ◽  
Post Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting

Abstract Background Hepatitis C virus virus is global health burden and major health hazard in Egypt, since the virus is the etiological factor of chronic hepatitis. Hepatitis C virus (HCV) accounts for approximately 15%-20% cases of acute hepatitis. After acute infection, around 50% to 80% of HCV patients will develop chronic infection. Approximately, HCV infects 170 million individuals worldwide). Chronic hepatitis C (CHC) patients are at high risk to develop lifethreatening complications, including cirrhosis in 20% of cases and hepatocellular carcinoma. Objectives The aim of this study was to validate Changes in serum level of autotaxin in patients with chronic hepatitis C before and after antiviral treatment. Patients and methods This study was designed as a prospective observational cohort study to evaluate Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C before (baseline) and after (sustained virologic response week 12) treatment. This prospective study was conducted on 48 chronic HCV infected patients eligible for antiviral treatment with direct acting antivirals, agreeable to regular follow up, recruited from Hepatology and virology outpatient clinic at DMNI (Damanhour Medical National Institute) during the period from September 2018 till Mars 2019. Results This study showed that Autotaxin level significantly decreased from baseline to 12 weeks post-treatment. ATX therefore represents a novel non-invasive biomarker for liver fibrosis and a prognostic indicator of disease activity. Conclusion Serum Autotaxin was found to be higher in chronic hepatitis c and ATX levels became significantly decreased from baseline to 12 weeks post-treatment with direct acting antiviral drugs in patients achieving a SVR.

Sign in / Sign up

Export Citation Format

Share Document